^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

brentuximab vedotin (Adcetris®) is accepted for use within NHSScotland

Published date:
12/04/2020
Excerpt:
brentuximab vedotin (Adcetris®) is accepted for use within NHSScotland...Indication under review: in combination with cyclophosphamide, doxorubicin and prednisone (CHP) for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
Secondary therapy:
doxorubicin hydrochloride + cyclophosphamide + prednisone
Evidence Level:
Sensitive: A1 - Approval
Published date:
10/25/2012
Excerpt:
Adcetris in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).
Secondary therapy:
doxorubicin hydrochloride + cyclophosphamide + prednisone
Evidence Level:
Sensitive: A1 - Approval
Published date:
10/25/2012
Excerpt:
Adcetris is indicated for the treatment of adult patients with relapsed or refractory sALCL.
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
ADCETRIS is a CD30-directed antibody-drug conjugate indicated for treatment of adult patients with… Previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
Secondary therapy:
doxorubicin hydrochloride + cyclophosphamide + prednisone
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
ADCETRIS is a CD30-directed antibody-drug conjugate indicated for treatment of adult patients with… Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.